Related references
Note: Only part of the references are listed.Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents
Caroline Machado Kopruszinski et al.
CEPHALALGIA (2017)
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart Tepper et al.
LANCET NEUROLOGY (2017)
Erenumab (AMG 334) in episodic migraine Interim analysis of an ongoing open-label study
Messoud Ashina et al.
NEUROLOGY (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING
Peter J. Goadsby et al.
PHYSIOLOGICAL REVIEWS (2017)
Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies
Dimos D. Mitsikostas et al.
CURRENT OPINION IN NEUROLOGY (2017)
Anti-CGRP monoclonal antibodies in migraine: current perspectives
Maria Adele Giamberardino et al.
INTERNAL AND EMERGENCY MEDICINE (2016)
AMG 334 CGRP antibody for migraine: time to celebrate?
Marta L. Ramos et al.
LANCET NEUROLOGY (2016)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Hong Sun et al.
LANCET NEUROLOGY (2016)
TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points
Marcelo E. Bigal et al.
NEUROLOGY (2016)
Wiping Out CGRP: Potential Cardiovascular Risks
Antoinette MaassenVanDenBrink et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor
Licheng Shi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Therapeutic antibodies against CGRP or its receptor
Marcelo E. Bigal et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
TEV-48125: a Review of a Monoclonal CGRP Antibody in Development for the Preventive Treatment of Migraine
Sarah Walter et al.
CURRENT PAIN AND HEADACHE REPORTS (2015)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal et al.
LANCET NEUROLOGY (2015)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal et al.
LANCET NEUROLOGY (2015)
Adherence to oral migraine-preventive medications among patients with chronic migraine
Zsolt Hepp et al.
CEPHALALGIA (2015)
Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program
Marcelo E. Bigal et al.
CEPHALALGIA (2014)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Anti-CGRP antibodies: a new approach to migraine prevention
Uwe Reuter
LANCET NEUROLOGY (2014)
CGRP as a new target in prevention and treatment of migraine Comment
Hans-Christoph Diener
LANCET NEUROLOGY (2014)
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
Tony W. Ho et al.
NEUROLOGY (2014)
Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies
Sieneke Labruijere et al.
EXPERT OPINION ON DRUG DISCOVERY (2013)
Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
Eva Cernuda-Morollon et al.
NEUROLOGY (2013)
Advances in understanding the mechanisms of migraine-type photophobia
Rodrigo Noseda et al.
CURRENT OPINION IN NEUROLOGY (2011)
CGRP and its receptors provide new insights into migraine pathophysiology
Tony W. Ho et al.
NATURE REVIEWS NEUROLOGY (2010)
CGRP receptors in the control of pain and inflammation
Silvia Benemei et al.
CURRENT OPINION IN PHARMACOLOGY (2009)
CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat
J. Zeller et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Migraine prevalence, disease burden, and the need for preventive therapy
R. B. Lipton et al.
NEUROLOGY (2007)
New and future migraine therapy
Nabih M. Ramadan et al.
PHARMACOLOGY & THERAPEUTICS (2006)
BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation
KA Petersen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
CGRP may play a causative role in migraine
LH Lassen et al.
CEPHALALGIA (2002)
Drug therapy: Migraine - Current understanding and treatment.
PJ Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
